Overview

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with obesity and metabolic syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Inversago Pharma Inc.